Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 28, 2013. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 502,000 Ordinary Shares of 25 pence each.
- Purchase Date: May 28, 2013.
- Price Range: Highest price paid was 1,813.5 pence per share; lowest price paid was 1,764.0 pence per share.
- Treasury Holdings: 500,092,012 shares held in Treasury (9.21% of total issued share capital).
- Total Voting Rights Impact: Including unsettled purchases, Treasury holdings represent 10.20% of total voting rights.
- Shares in Issue: 4,928,213,781 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 502,000 shares for Treasury. This transaction increased the proportion of shares held in Treasury relative to total voting rights to 10.20% when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (500,092,012) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.20% held in Treasury including unsettled shares).
- Check the average price paid per share against the reported range (1,764.0 to 1,813.5 pence).
- Review the total issued share capital to validate the 9.21% Treasury holding percentage.